XML 59 R41.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($) $ in Thousands |  | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Jul. 30, 2013 | Dec. 31, 2020 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2015 | Jun. 30, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Deferred Revenue |  | $ 6,547 | $ 15,857 | $ 6,547 |  |  |
Deferred revenue ($3,201 and $2,907 to related parties) |  | 6,547 | 15,857 | 6,547 |  |  |
Total revenue |  |  | 235,309 | 176,319 | $ 256,577 |  |
Product Revenue, Net [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Total revenue |  |  | 47,638 | 72,498 | 1,700 |  |
Drug Product Revenue [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Total revenue |  |  | 962 | 8,906 | (36,324) |  |
AstraZeneca Agreements [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Transaction price and allocated to performance obligations |  |  |  |  |  |  | $ 50,000
Revenue during period from performance obligations |  |  |  |  | 42,400 |  |
Milestone payment received |  |  | 35,568 |  |  |  |
AstraZeneca Agreements [Member] | Selling, General and Administrative Expenses [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Reversal of accrued co-promotion expenses |  | 84,400 |  |  |  |  |
Co-promotion expenses |  |  | 4,700 | 27,200 |  |  |
AstraZeneca Agreements [Member] | Drug Product Revenue [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Deferred Revenue |  |  | 11,200 |  |  |  |
Deferred revenue ($3,201 and $2,907 to related parties) |  |  | 11,200 |  |  |  |
Total revenue |  |  | $ (2,224) | 4,625 | 0 |  |
AstraZeneca Agreements [Member] | U.S./RoW [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Upfront, non-contingent, non-refundable and time-based payments | $ 374,000 |  |  |  |  |  |
Potential milestone payments | 875,000 |  |  |  |  |  |
Commercial sales milestone | 325,000 |  |  |  |  |  |
Shared development costs |  |  |  |  |  | $ 233,000 |
Additional consideration based on net sales description |  |  | low 20% range |  |  |  |
Aggregate considerations received excluding drug product revenue |  |  | $ 439,000 |  |  |  |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | FibroGen, Inc. [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Shared development costs |  |  |  |  |  | $ 116,500 |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Clinical and Development Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | 65,000 |  |  |  |  |  |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Regulatory Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | 325,000 |  |  |  |  |  |
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Deferred Approval Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | 160,000 |  |  |  |  |  |
AstraZeneca Agreements [Member] | China [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | 348,500 |  |  |  | 22,000 |  |
Transaction price and allocated to performance obligations |  |  |  |  | 22,000 |  |
Deferred Revenue |  | 7,000 | 7,900 | 7,000 |  |  |
Proceeds from upfront, non-contingent and non-refundable payments | 28,200 |  |  |  |  |  |
Commercial sales and other events milestone | 187,500 |  |  |  |  |  |
Aggregate considerations received |  |  | 77,200 |  |  |  |
Milestone payment received |  |  |  |  | 18,700 |  |
Deferred revenue ($3,201 and $2,907 to related parties) |  | 7,000 | 7,900 | 7,000 |  |  |
Total revenue |  |  | 0 | (90) | 90 |  |
AstraZeneca Agreements [Member] | China [Member] | Product Revenue, Net [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Total revenue |  |  | 35,600 |  |  |  |
AstraZeneca Agreements [Member] | China [Member] | Accrued and Other Current Liabilities [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Deferred Revenue |  | 7,000 | 7,900 | 7,000 |  |  |
Deferred revenue ($3,201 and $2,907 to related parties) |  | $ 7,000 | 7,900 | 7,000 |  |  |
AstraZeneca Agreements [Member] | China [Member] | Clinical and Development Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | 15,000 |  |  |  |  |  |
AstraZeneca Agreements [Member] | China [Member] | Regulatory Milestone [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Potential milestone payments | $ 146,000 |  |  |  |  |  |
Direct Sales [Member] | Product Revenue, Net [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Total revenue |  |  | 12,070 | $ 72,498 | $ 1,700 |  |
Direct Sales [Member] | China [Member] | Product Revenue, Net [Member] |  |  |  |  |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |
Total revenue |  |  | $ 12,100 |  |  |  |

X
- Definition The amount of additional consideration based on net sales of product as defined under a collaboration agreement. + References No definition available. + Details
Name: | fgen_AdditionalConsiderationBasedOnNetSales
Namespace Prefix: | fgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Co-promotion expenses. + References No definition available. + Details
Name: | fgen_CoPromotionExpenses
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of aggregate consideration receivable under collaborative arrangement. + References No definition available. + Details
Name: | fgen_CollaborativeArrangementAggregateConsideration
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue. + References No definition available. + Details
Name: | fgen_CollaborativeArrangementAggregateConsiderationExcludingDrugProductRevenue
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Commercial sales and other events milestone. + References No definition available. + Details
Name: | fgen_CommercialSalesAndOtherEventsMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payments related to commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_CommercialSalesMilestone
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement. + References No definition available. + Details
Name: | fgen_PotentialMilestones
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentAndNonRefundablePayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration. + References No definition available. + Details
Name: | fgen_ProceedsFromUpfrontNonContingentNonRefundableAndTimeBasedPayments
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Reversal of accrued co-promotion expenses. + References No definition available. + Details
Name: | fgen_ReversalOfAccruedCoPromotionExpenses
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the total amount of development costs that will be shared under collaborative agreement. + References No definition available. + Details
Name: | fgen_SharedDevelopmentCosts
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Transaction price allocated to performance obligations. + References No definition available. + Details
Name: | fgen_TransactionPriceAllocatedToPerformanceObligations
Namespace Prefix: | fgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ValuationAllowancesAndReservesTypeAxis=fgen_DrugProductRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=fgen_UnitedStatesAndRestOfWorldMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=fgen_FibroGenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_ClinicalDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=fgen_DeferredApprovalMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=fgen_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=fgen_DirectSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |